341 related articles for article (PubMed ID: 25312300)
21. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
22. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.
Wu PA; Kim YH; Lavori PW; Hoppe RT; Stockerl-Goldstein KE
Biol Blood Marrow Transplant; 2009 Aug; 15(8):982-90. PubMed ID: 19589488
[TBL] [Abstract][Full Text] [Related]
23. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcome of allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a European society for blood and marrow transplantation lymphoma working party extended analysis.
Duarte RF; Boumendil A; Onida F; Gabriel I; Arranz R; Arcese W; Poiré X; Kobbe G; Narni F; Cortelezzi A; Olavarría E; Schmitz N; Sureda A; Dreger P
J Clin Oncol; 2014 Oct; 32(29):3347-8. PubMed ID: 25154828
[No Abstract] [Full Text] [Related]
25. Advanced-stage mycosis fungoides and Sézary syndrome: survival and response to treatment.
Alberti-Violetti S; Talpur R; Schlichte M; Sui D; Duvic M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e105-12. PubMed ID: 25817937
[TBL] [Abstract][Full Text] [Related]
26. Molecular staging of lymph nodes from 60 patients with mycosis fungoides and Sézary syndrome: correlation with histopathology and outcome suggests prognostic relevance in mycosis fungoides.
Fraser-Andrews EA; Mitchell T; Ferreira S; Seed PT; Russell-Jones R; Calonje E; Whittaker SJ
Br J Dermatol; 2006 Oct; 155(4):756-62. PubMed ID: 16965425
[TBL] [Abstract][Full Text] [Related]
27. Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced-intensity conditioning.
Kahata K; Hashino S; Takahata M; Fujisawa F; Kondo T; Kobayashi S; Fujita Y; Shimizu H; Imamura M; Asaka M
Acta Haematol; 2008; 120(1):14-8. PubMed ID: 18716396
[TBL] [Abstract][Full Text] [Related]
28. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
Berg S; Villasenor-Park J; Haun P; Kim EJ
Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
[TBL] [Abstract][Full Text] [Related]
29. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
[TBL] [Abstract][Full Text] [Related]
30. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
[TBL] [Abstract][Full Text] [Related]
31. Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.
Hughes CF; Newland K; McCormack C; Lade S; Prince HM
Australas J Dermatol; 2016 Aug; 57(3):182-91. PubMed ID: 25988337
[TBL] [Abstract][Full Text] [Related]
32. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft-versus-tumor effect.
Burt RK; Guitart J; Traynor A; Link C; Rosen S; Pandolfino T; Kuzel TM
Bone Marrow Transplant; 2000 Jan; 25(1):111-3. PubMed ID: 10654025
[TBL] [Abstract][Full Text] [Related]
33. Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas.
Isufi I; Seropian S; Gowda L; Wilson LD; Roberts K; Girardi M; Perreault S; Foss F
Leuk Lymphoma; 2020 Dec; 61(12):2955-2961. PubMed ID: 32643494
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
Servais S; Baron F; Beguin Y
Transfus Apher Sci; 2011 Apr; 44(2):205-10. PubMed ID: 21345734
[TBL] [Abstract][Full Text] [Related]
35. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
36. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
[TBL] [Abstract][Full Text] [Related]
37. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of reduced-intensity allogeneic hematopoietic stem cell transplantation for refractory or relapsed follicular lymphoma.
Ono Y; Mori T; Kato J; Yamane A; Shimizu T; Kikuchi T; Kohashi S; Okamoto S
Am J Hematol; 2012 Sep; 87(9):929-31. PubMed ID: 22674621
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study.
de Masson A; Beylot-Barry M; Ram-Wolff C; Mear JB; Dalle S; d'Incan M; Ingen-Housz-Oro S; Orvain C; Abraham J; Dereure O; Charbonnier A; Cornillon J; Longvert C; Barete S; Boulinguez S; Wierzbicka-Hainaut E; Aubin F; Rubio MT; Bernard M; Schmidt-Tanguy A; Houot R; Pham-Ledard A; Michonneau D; Brice P; Labussière-Wallet H; Bouaziz JD; Grange F; Moins-Teisserenc H; Jondeau K; Michel L; Mourah S; Battistella M; Daguindau E; Loschi M; Picard A; Franck N; Maillard N; Huynh A; Nguyen S; Marçais A; Chaby G; Ceballos P; Le Corre Y; Maury S; Bay JO; Adamski H; Bachy E; Forcade E; Socié G; Bagot M; Chevret S; Peffault de Latour R; ; ;
Lancet; 2023 Jun; 401(10392):1941-1950. PubMed ID: 37105210
[TBL] [Abstract][Full Text] [Related]
40. Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A; Mohr C; Guillaume T; Delaunay J; Malard F; Loirat M; Peterlin P; Blin N; Dubruille V; Mahe B; Gastinne T; Le Gouill S; Moreau P; Mohty M; Planche L; Lode L; Bene MC; Chevallier P
Biol Blood Marrow Transplant; 2013 Jun; 19(6):934-9. PubMed ID: 23523970
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
